SciTech Development, a clinical-stage pharmaceutical company focused on advancements in cancer treatment, is excited to share promising updates from its clinical trial of ST-001 nanoFenretinide (ST-001). Preliminary Trial Findings: Preliminary...
French TechBio startup Cure51 and 10x Genomics, Inc., a leader in single cell and spatial biology, announced that Cure51 will deploy 10x Genomics' Visium HD as part of its pioneering work to understand the unique biology of exceptional cancer...
GC Biopharma announced that it has signed an agreement with Novelty Nobility, a biotech company specializing in the development of antibody-based therapeutics, for the joint research and development of a novel treatment for geographic atrophy...
BioCryst Pharmaceuticals, Inc. announced new real-world comparative research on the use of oral, once-daily ORLADEYO® (berotralstat) that found high rates of adherence and persistence for ORLADEYO, similar to the rates observed with two other...
2nd International Conference on Biotechnology and Bioengineering, a Hybrid Event scheduled from October 24-25, 2024, Paris, France. We cordially invite competitors from all corners of the globe to showcase their expertise, talents, and research in...
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, announced that the first participant has been dosed in the Randomized Placebo Controlled Double Blind...
Zydus Lifesciences Ltd., a global innovation driven pharma company that its wholly owned subsidiary, Zydus Lifesciences Global FZE has entered into an exclusive licensing and supply agreement with Viwit Pharmaceuticals (Viwit), an innovation...
City of Hope®, one of the largest cancer research and treatment organizations in the United States, and Biopharmaceutical Research Company (BRC), a specialty pharmaceutical company developing proprietary cannabinoid therapeutics, announced that...
Australia Vaxxas announced that it has initiated a multi-center Phase I clinical trial of a vaccine against pre-pandemic avian influenza strain H7N9, using the company’s high-density microarray patch (HD-MAP). Conducted in collaboration with...
Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the appointment of Sergio Santillana, MD, MSc, MBA, as Chief Medical...
Corundum Systems Biology, a leading investment company dedicated to advancing life-changing systems biology solutions for human health and well-being, today announced it has appointed Jessica Schneider, PhD, MPH as Chief Scientific Officer (CSO)....
ProJenX, Inc., a clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined pathways for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, announced the...
Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi® (seladelpar) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in...
Citius Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved LYMPHIR™ (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of r/r cutaneous T-cell lymphoma (CTCL) after at least one prior...
Lipella Pharmaceuticals Inc. a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the enrollment of the first patients in its multi-center Phase 2a clinical trial evaluating LP-310 for the...
T3D Therapeutics, Inc., a clinical stage drug development company engaged in the development of a new orally administered treatment for Alzheimer's disease (AD), announced that CEO, John Didsbury, will be presenting new Phase 2 results in a...
SHINE Technologies, a next-generation fusion company, will showcase FLARE™, the world's most powerful continuous fusion neutron system, at the IEEE Nuclear & Space Radiation Effects and at the Technology of Fusion Energy Meeting (TOFE). FLARE,...
Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders with a focus on validated targets in cancer and inflammatory diseases, announced that the first patient has been dosed in its...
Cytonics Corporation, a private biotechnology company developing biologic therapies for musculoskeletal ailments, announced initiation of enrollment for its Phase 1 clinical study of CYT-108. A recombinant variant of the alpha-2-macroglobulin...
AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY® (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody administered subcutaneously for the treatment of adults with relapsed or...
